Fujioka, K
Plodkowski, R
O'Neil, P M
Gilder, K
Walsh, B
Greenway, F L
Article History
Received: 24 July 2015
Revised: 20 March 2016
Accepted: 4 April 2016
First Online: 22 June 2016
Competing interests
: Clinical trials funded by: Orexigen Therapeutics, Inc., La Jolla, CA. The manuscript was supported by Orexigen and Takeda Pharmaceuticals International, Inc., Deerfield, IL. Ken Fujioka: Research grants from: Orexigen, Novo Nordisk, Enteromedics, Eisai, Takeda, and Weight Watchers. Consultant for: Novo Nordisk, Enteromedics, Zafgen, Eisai, Nazura, Takeda, and Isis. Speakers Bureau for: Abbott, NPS, Eisai, and Takeda. Patrick O'Neil: Research funding from: Orexigen, Weight Watchers, Novo Nordisk. Advisory Board for: Orexigen and Novo Nordisk. Honoraria from: Vivus, Eisai, Novo Nordisk, Medscape. Raymond Plodkowski: Research funding from: Orexigen, and Speakers Bureau for Takeda. Brandon Walsh: Employee and stockholder, Orexigen. Kye Gilder: Employee and stockholder, Orexigen. Frank Greenway: Consultant for: Basic Research, Eisai, General Nutrition Corporation, Neothetics, Obalon Therapeutics, Pam labs, Takeda, and Techenterprises. Scientific Advisory Board for: Baronova, Jenny Craig/Curves, Novo Nordisk, Orexigen, and Zafgen. Licensed patents with: Neuroquest. Stock options with Neothetics, and stock with OriginBiomed.